Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | GJB2 | P29033 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.49 |
| ▸ | CDC25B | P30305 | 8/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982235 | 0.89 | SLC6A2 (0.61) | SLC6A2GJB2PTPN1CDC25BPTPN2 | |
| SCHEMBL4982239 | 0.89 | SLC6A2 (0.61) | SLC6A2GJB2PTPN1CDC25BPTPN2 | |
| SCHEMBL1776650 | 0.89 | PTPN1 (0.52) | GJB2PTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL1776647 | 0.89 | PTPN1 (0.52) | GJB2PTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL13608236 | 0.88 | PTPN1 (0.53) | SLC6A2GJB2PTPN1CDC25BPTPN2 | |
| SCHEMBL13058726 | 0.88 | GJB2 (0.54) | GJB2PTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL3766123 | 0.88 | GJB2 (0.54) | GJB2PTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL13058715 | 0.86 | GJB2 (0.58) | GJB2PTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL3758159 | 0.86 | GJB2 (0.58) | GJB2PTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL13058741 | 0.86 | GJB2 (0.58) | GJB2PTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361744-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20060025350-A1 | Oligosaccharide derivative | SANKYO COMPANY, LIMITED (JP) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025350-A1 | Oligosaccharide derivative | MAN1B1, FUT6, MAN2A1 | SLC6A2 4529/4885GJB2 4783/4885PTPN1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.